Blood Cancer Discovery with Dr. Jaroslaw Maciejewski and Dr. Babal Jha
Moderated by: Tanya Bondar, PhD
Blood Cancer Discovery Deputy Editor
Watch the recording of the AACR Journal Club session featuring Jaroslaw Maciejewski, MD, PhD, and Babal Jha, PhD, discussing their article published in Blood Cancer Discovery, "Minimal TET activity is a targetable vulnerability of Tet2 and neomorphic IDH1/2-mutant myeloid malignancies." TET dioxygenases are commonly inactivated in myeloid neoplasms genetically or by 2-hydroxyglutarate (2HG) product of mutant IDH1 enzymes. This work shows that minimal TET activity is essential for neoplastic cell survival and underlies synthetic lethality of TET and IDH mutations. To prove the concept and harness it for therapy, the authors have developed a mimetic of 2HG, which mirrors synthetic lethality of IDH mutation in TET2-deficient background and restricts clonal outgrowth of TET2-mutant cells in models of myeloid neoplasms.
Stay tuned for the Q&A session at the end of the recording.
About the Featured Speakers:
Babal Kant Jha, PhD, is an Assistant Professor at the Cleveland Clinic Lerner College of Medicine and an Adjunct Assistant Professor in the Department of Molecular Medicine at the Case Comprehensive Cancer Center.
Jaroslaw Maciejewski, MD, PhD, is a Professor in the Department of Medicine and Associate Director for Translational Research as well as Co-Leader for the Hematopoietic and Immune Cancer Biology Program at the Case Comprehensive Cancer Center. He is also the Chairman of the Department of Translational Hematology and Oncology Research at the Taussig Cancer Institute.